Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Marcin Waligora"'
Autor:
Nora Hutchinson, Katarzyna Klas, Benjamin G. Carlisle, Maciej Polak, Jonathan Kimmelman, Marcin Waligora
Publikováno v:
BMC Research Notes, Vol 15, Iss 1, Pp 1-5 (2022)
Abstract Objective Competition among trials for patient enrollment can impede recruitment. We hypothesized that this occurred early in the COVID-19 pandemic, when an unprecedented number of clinical trials were launched. We performed a simple and mul
Externí odkaz:
https://doaj.org/article/16f56c42e336488196c17ff4dab89203
Autor:
Karolina Strzebonska, Mateusz Blukacz, Mateusz T. Wasylewski, Maciej Polak, Bishal Gyawali, Marcin Waligora
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-16 (2022)
Abstract Background Umbrella clinical trials in precision oncology are designed to tailor therapies to the specific genetic changes within a tumor. Little is known about the risk/benefit ratio for umbrella clinical trials. The aim of our systematic r
Externí odkaz:
https://doaj.org/article/fde121abb1274be4bdfa675f15665d8f
Autor:
Milosz Pietrus, Kazimierz Pitynski, Marcin Waligora, Katarzyna Milian-Ciesielska, Artur Ludwin, Maciej W. Socha, Klaudia Skrzypek
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 9, p 8342 (2023)
Endometrial cancer remains a common cancer affecting the female reproductive system. There is still a need for more efficient ways of determining the degree of malignancy and optimizing treatment. WNT and mTOR are components of signaling pathways wit
Externí odkaz:
https://doaj.org/article/f2e236925db041539df73314f4264508
Publikováno v:
PLoS ONE, Vol 17, Iss 1 (2022)
Background Early in the SARS-CoV-2 pandemic, commentators warned that some COVID trials were inadequately conceived, designed and reported. Here, we retrospectively assess the prevalence of informative COVID trials launched in the first 6 months of t
Externí odkaz:
https://doaj.org/article/efbb2625b16742c79e16cb3d6e4d580f
Autor:
Karolina Strzebonska, Marcin Waligora
Publikováno v:
BMC Medical Ethics, Vol 20, Iss 1, Pp 1-10 (2019)
Abstract Background Novel precision oncology trial designs, such as basket and umbrella trials, are designed to test new anticancer agents in more effective and affordable ways. However, they present some ethical concerns referred to scientific valid
Externí odkaz:
https://doaj.org/article/6fc963a104cc4110a6515ee2c4949d79
Autor:
Mateusz T Wasylewski, Karolina Strzebonska, Magdalena Koperny, Maciej Polak, Jonathan Kimmelman, Marcin Waligora
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234911 (2020)
ObjectivesDrug development trials must fulfill social value requirement but no estimates of value provided by pediatric Phase 1 trials in oncology exist. These trials involve a particularly vulnerable population. Our objective was to assess of surrog
Externí odkaz:
https://doaj.org/article/f7890a9443524ad9b8ed8961926557e2
Autor:
Marcin Waligora, Malgorzata M Bala, Magdalena Koperny, Mateusz T Wasylewski, Karolina Strzebonska, Rafał R Jaeschke, Agnieszka Wozniak, Jan Piasecki, Agnieszka Sliwka, Jerzy W Mitus, Maciej Polak, Dominika Nowis, Dean Fergusson, Jonathan Kimmelman
Publikováno v:
PLoS Medicine, Vol 15, Iss 2, p e1002505 (2018)
BACKGROUND:Pediatric Phase I cancer trials are critical for establishing the safety and dosing of anti-cancer treatments in children. Their implementation, however, must contend with the rarity of many pediatric cancers and limits on allowable risk i
Externí odkaz:
https://doaj.org/article/78717fdf37444366a52d4ee30a8f21ea
Publikováno v:
Medicine, Health Care and Philosophy. 26:233-241
Drug repurposing is a strategy of identifying new potential uses for already existing drugs. Many researchers adopted this method to identify treatment or prevention during the COVID-19 pandemic. However, despite the considerable number of repurposed
Autor:
Aleksandra Mamzer, Marcin Waligora, Grzegorz Kopec, Katarzyna Ptaszynska-Kopczynska, Marcin Kurzyna, Szymon Darocha, Michal Florczyk, Ewa Mroczek, Tatiana Mularek-Kubzdela, Anna Smukowska-Gorynia, Michal Wrotynski, Lukasz Chrzanowski, Olga Dzikowska-Diduch, Katarzyna Perzanowska-Brzeszkiewicz, Piotr Pruszczyk, Ilona Skoczylas, Ewa Lewicka, Piotr Blaszczak, Danuta Karasek, Beata Kusmierczyk-Droszcz, Katarzyna Mizia-Stec, Karol Kaminski, Wojciech Jachec, Malgorzata Peregud-Pogorzelska, Anna Doboszynska, Zbigniew Gasior, Michal Tomaszewski, Agnieszka Pawlak, Wieslawa Zablocka, Robert Ryczek, Katarzyna Widejko-Pietkiewicz, Jaroslaw D. Kasprzak
Publikováno v:
International Journal of Environmental Research and Public Health; Volume 19; Issue 14; Pages: 8423
We aimed to evaluate the clinical course and impact of the SARS-CoV-2 pandemic on the rate of diagnosis and therapy in the complete Polish population of patients (pts) with pulmonary arterial hypertension (PAH-1134) and CTEPH (570 pts) treated within